GNI Group (JP:2160) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GNI Group Ltd. has announced that their subsidiary GYRE Pharmaceuticals’ new drug, Avatrombopag Maleate Tablets, for treating thrombocytopenia in chronic liver disease patients, has been approved by China’s National Medical Products Administration. This addition expands the company’s portfolio, which includes treatments for rare diseases, although it is expected to have a minor impact on the fiscal year’s consolidated financial results.
For further insights into JP:2160 stock, check out TipRanks’ Stock Analysis page.